Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglyc...

Полное описание

Библиографические подробности

Главные авторы:	Weixiang Chen, Yue Zhang, Zuoxiang Wang, Mingyue Tan, Jia Lin, Xiaodong Qian, Hongxia Li, Tingbo Jiang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2023-02-01
Серии:	Frontiers in Pharmacology
Предметы:	myocardial ischemia/reperfusion dapagliflozin ferroptosis MAPK pathway treatment
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1078205/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!